Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions DOI Creative Commons
Lei‐Ming Cao, Yifu Yu, Zi‐Zhan Li

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: June 2, 2024

Abstract Research into mRNA vaccines is advancing rapidly, with proven efficacy against coronavirus disease 2019 and promising therapeutic potential a variety of solid tumors. Adjuvants, critical components vaccines, significantly enhance vaccine effectiveness are integral to numerous formulations. However, the development selection adjuvant platforms still in their nascent stages, mechanisms many adjuvants remain poorly understood. Additionally, immunostimulatory capabilities certain novel drug delivery systems (DDS) challenge traditional definition adjuvants, suggesting that revision this concept necessary. This review offers comprehensive exploration applications self-adjuvant DDS. It thoroughly addresses existing issues mentioned above details three main challenges immune-related adverse event, unclear mechanisms, unsatisfactory outcomes old age group design practical application cancer adjuvants. Ultimately, proposes optimization strategies which consists exploring adjuvant, optimizing DDS, improving route administration improve

Language: Английский

Vaccine adjuvants: mechanisms and platforms DOI Creative Commons
Tingmei Zhao,

Yulong Cai,

Yujie Jiang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: July 19, 2023

Abstract Adjuvants are indispensable components of vaccines. Despite being widely used in vaccines, their action mechanisms not yet clear. With a greater understanding the by which innate immune response controls antigen-specific response, adjuvants’ beginning to be elucidated. can categorized as immunostimulants and delivery systems. Immunostimulants danger signal molecules that lead maturation activation antigen-presenting cells (APCs) targeting Toll-like receptors (TLRs) other pattern recognition (PRRs) promote production antigen signals co-stimulatory signals, turn enhance adaptive responses. On hand, systems carrier materials facilitate presentation prolonging bioavailability loaded antigens, well antigens lymph nodes or APCs. The systematically summarized at this review. This is followed an introduction mechanisms, properties, progress classical vaccine adjuvants. Furthermore, since some adjuvants under investigation exhibit potency than adjuvants, could compensate for deficiencies summary adjuvant platforms subsequently presented. Notably, we highlight different immunological properties these platforms, will provide wide range options rational design basis, review points out development prospects problems should paid attention future.

Language: Английский

Citations

342
Type I interferon-mediated tumor immunity and its role in immunotherapy DOI Creative Commons

Renren Yu,

Bo Zhu, Degao Chen

et al.

Cellular and Molecular Life Sciences, Journal Year: 2022, Volume and Issue: 79(3)

Published: March 1, 2022

Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant even hyperprogressive. Type I interferons (IFNs) been demonstrated inhibit tumor growth directly indirectly by acting upon immune cells, respectively. Furthermore, accumulating evidence indicates that endo- exogenously enhancing type IFNs a synergistic effect on anti-tumor immunity. Therefore, trials studying new treatment strategies combine IFN inducers are currently progress. Here, we review the cellular sources their roles regulation microenvironment. In addition, highlight immunotherapies based combination therapy between ICBs.

Language: Английский

Citations

190
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives DOI Creative Commons
Alessio Facciolà, Giuseppa Visalli, A. Laganà

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(5), P. 819 - 819

Published: May 22, 2022

Vaccinations are one of the most important preventive tools against infectious diseases. Over time, many different types vaccines have been developed concerning antigen component. Adjuvants essential elements that increase efficacy vaccination practises through actions, especially acting as carriers, depots, and stimulators immune responses. For years, few adjuvants included in vaccines, with aluminium salts being commonly used adjuvant. However, recent research has focused its attention on new compounds effective adjuvant properties improved safety. Modern technologies such nanotechnologies molecular biology forcefully entered production processes both components, thereby improving vaccine efficacy. Microparticles, emulsions, currently spotlight for their huge potential production. Although studies reported some side effects recently recognised ASIA syndrome, worth remains unquestionable. Indeed, COVID-19 pandemic highlighted importance regard to managing future pandemics. In this field, into could play a leading role increasingly vaccines.

Language: Английский

Citations

168
Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics DOI Creative Commons
Arshpreet Kaur, Jeremy Baldwin, Deshkanwar Brar

et al.

Current Opinion in Chemical Biology, Journal Year: 2022, Volume and Issue: 70, P. 102172 - 102172

Published: July 1, 2022

Language: Английский

Citations

109
A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion DOI Open Access
Seung Mo Jin, Yeon Jeong Yoo,

Hong Sik Shin

et al.

Nature Nanotechnology, Journal Year: 2023, Volume and Issue: 18(4), P. 390 - 402

Published: Jan. 12, 2023

Language: Английский

Citations

70
Materials engineering strategies for cancer vaccine adjuvant development DOI Creative Commons
Xuanbo Zhang,

Bowei Yang,

Qianqian Ni

et al.

Chemical Society Reviews, Journal Year: 2023, Volume and Issue: 52(9), P. 2886 - 2910

Published: Jan. 1, 2023

Cancer vaccines have emerged as a powerful new tool for cancer immunotherapy. Adjuvants are vaccine ingredients that enhance the strength, velocity, and duration of immune response. The success adjuvants in achieving stable, safe, immunogenic has generated enthusiasm adjuvant development. Specifically, advances materials science providing insights into rational design topical Here, we outline current state engineering strategies, including those based on molecular adjuvants, polymers/lipids, inorganic nanoparticles, bio-derived materials, We also elaborate how these strategies physicochemical features involved influence effects adjuvants.

Language: Английский

Citations

59
Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy DOI Creative Commons
Mingqi Liu, Yang Feng, Yougong Lu

et al.

Science Advances, Journal Year: 2024, Volume and Issue: 10(11)

Published: March 13, 2024

Cancer vaccines show huge potential for cancer prevention and treatment. However, their efficacy remains limited due to weak immunogenicity regarding inefficient stimulation of cytotoxic T lymphocyte (CTL) responses. Inspired by the unique characteristic biological function high-density lipoprotein (HDL), we here develop an HDL-mimicking nanovaccine with commendable lymph-targeted capacity potently elicit antitumor immunity using lipid nanoparticle that is co-loaded specific cytomembrane harboring a collection tumor-associated antigens immune adjuvant. The nanoparticulate impact explored on efficiency lymphatic targeting dendritic cell uptake. optimized promotes co-delivery adjuvants lymph nodes maintains antigen presentation cells, resulting in long-term surveillance as elevated frequency CTLs within lymphoid organs tumor tissue. Immunization suppresses formation growth augments therapeutic checkpoint inhibitors notably high-stemness melanoma mouse models.

Language: Английский

Citations

35
Locoregional drug delivery for cancer therapy: Preclinical progress and clinical translation DOI
Suyog Shaha, Danika Rodrigues, Samir Mitragotri

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 367, P. 737 - 767

Published: Feb. 14, 2024

Language: Английский

Citations

25
Engineered Bio‐Based Hydrogels for Cancer Immunotherapy DOI
Yuxuan Peng, Shuang Liang, Qian‐Fang Meng

et al.

Advanced Materials, Journal Year: 2024, Volume and Issue: 36(21)

Published: Feb. 16, 2024

Immunotherapy represents a revolutionary paradigm in cancer management, showcasing its potential to impede tumor metastasis and recurrence. Nonetheless, challenges including limited therapeutic efficacy severe immune-related side effects are frequently encountered, especially solid tumors. Hydrogels, class of versatile materials featuring well-hydrated structures widely used biomedicine, offer promising platform for encapsulating releasing small molecule drugs, biomacromolecules, cells controlled manner. Immunomodulatory hydrogels present unique capability augmenting immune activation mitigating systemic toxicity through encapsulation multiple components localized administration. Notably, based on biopolymers have gained significant interest owing their biocompatibility, environmental friendliness, ease production. This review delves into the recent advances bio-based immunotherapy synergistic combinatorial approaches, highlighting diverse applications. It is anticipated that this will guide rational design field immunotherapy, fostering clinical translation ultimately benefiting patients.

Language: Английский

Citations

24
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review DOI Creative Commons

Alessandra Cesano,

Ryan C. Augustin, Luigi Barrea

et al.

Journal for ImmunoTherapy of Cancer, Journal Year: 2025, Volume and Issue: 13(1), P. e008876 - e008876

Published: Jan. 1, 2025

Cancer immunotherapy-including immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT)-has become a standard, potentially curative treatment for subset of advanced solid liquid tumors. However, most patients with cancer do not benefit from the rapidly evolving improvements in understanding principal mechanisms determining responsiveness (CIR); including patient-specific genetically determined acquired factors, as well intrinsic biology. Though CIR is multifactorial, fundamental concepts are emerging that should be considered design novel therapeutic strategies related clinical studies. Recent advancements approaches to address limitations current treatments discussed here, specific focus on ICI ACT.

Language: Английский

Citations

2